Nervous System Neoplasms: Clinical Trials

1778 completed, 689 recruiting, 488 unknown, 440 terminated. 1288 Phase 2, 968 Phase 1, 799 Not applicable, 315 Phase 3, 104 Early Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	1288	Completed 591, Terminated 186, Recruiting 181, Unknown 129, Active not recruiting 95, Withdrawn 60, Not yet recruiting 37, Suspended 7, Enrolling by invitation 2
Phase 1	968	Completed 488, Terminated 140, Recruiting 139, Active not recruiting 81, Withdrawn 45, Unknown 39, Not yet recruiting 26, Suspended 7, Enrolling by invitation 3
Not applicable	799	Completed 289, Recruiting 178, Unknown 123, Terminated 61, Not yet recruiting 47, Active not recruiting 45, Withdrawn 40, Enrolling by invitation 8, Suspended 8
Phase 3	315	Completed 146, Recruiting 47, Unknown 44, Active not recruiting 31, Terminated 29, Not yet recruiting 9, Withdrawn 7, Enrolling by invitation 2
Early Phase 1	104	Completed 35, Recruiting 20, Terminated 18, Not yet recruiting 11, Withdrawn 8, Active not recruiting 7, Unknown 4, Enrolling by invitation 1
Phase 4	75	Completed 35, Unknown 15, Recruiting 12, Terminated 4, Withdrawn 3, Active not recruiting 2, Enrolling by invitation 2, Not yet recruiting 2

Follow Nervous System Neoplasms: new trials by email Literature Review of Nervous System Neoplasms trials Research Report on Nervous System Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas RNS System Implantation - Glioma, Glioma Intracranial	Not applicable	Not yet recruiting	Medical College of Wisconsin	3	2028-08-01	2026-10-13
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease	Phase 1 / Phase 2	Not yet recruiting	Jubilant Therapeutics Inc.	113	2028-04-01	2026-08-07
A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients Aminolevulinic acid hydrochloride - Pediatric Brain Tumor	Phase 2	Not yet recruiting	Costas Hadjipanayis	20	2027-08-01	2026-10-07
H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	30	2027-06-30	2026-08-27
Use of Shear Wave Elastography for Intraoperative Brain and Tumor Stiffness Measurements Non-Interventional Study - Brain Tumor, Recurrent Brain Tumor		Not yet recruiting	Mayo Clinic	30	2027-06-01	2026-09-16
Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG Myasthenia Gravis Generalized		Not yet recruiting	BioSensics	25	2027-03-15	2026-10-13
Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma	Phase 2	Not yet recruiting	Nationwide Children's Hospital	12	2027-03-01	2026-09-09
Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) Tovorafenib - High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV)	Phase 2	Not yet recruiting	Nationwide Children's Hospital	79	2027-02-01	2026-10-20
IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4	Phase 2	Not yet recruiting	German Cancer Research Center	216	2027-02-01	2026-10-22
Mirdametinib to Reduce the Size of Large/Giant Congenital Melanocytic Nevi in Children, Adolescents and Young Adults Mirdametinib - LGCMN, Large and Giant Congenital Melanocytic Nevi	Phase 2	Not yet recruiting	National Cancer Institute (NCI)	15	2027-01-04	2026-10-23
Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases Trastuzumab Deruxtecan, Stereotactic Radiosurgery - Breast Cancer, HER2-positive Breast Cancer	Phase 1	Not yet recruiting	Baptist Health South Florida	20	2027-01-01	2026-10-01
Role of ChatGPT in Vestibular Schwannoma Management Use of chatGPT for 1 week - Vestibular Schwannoma	Not applicable	Withdrawn	University of Southern California		2027-01-01	2026-01-13
Listen Aphasia Pilot Study LISTEN (AI-based AAC smartphone app) - Aphasia, Malignant Brain Tumor	Not applicable	Not yet recruiting	Dana-Farber Cancer Institute	80	2027-01-01	2026-07-28
A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar Spine 3D-printed custom-made non-rigid biomimetic implant - Spinal Tumor	Not applicable	Not yet recruiting	National Taiwan University Hospital	18	2027-01-01	2025-12-17
ctDNA-Guided Intraventricular Therapy for CNS Malignancies CSF ctDNA-Guided Clinical Management - Leptomeningeal Disease, Glioblastoma	Not applicable	Not yet recruiting	Alireza Mansouri	77	2027-01-01	2026-07-08
Ceritinib Treatment for Recurrent Meningiomas Ceritinib - Recurrent Meningioma, Grade I and Grade II	Phase 2	Not yet recruiting	Kevin Petrecca	10	2027-01-01	2026-10-23
Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor avutometinib capsule + defactinib tablet - MPNST (Malignant Peripheral Nerve Sheath Tumor)	Phase 2	Not yet recruiting	Girish Dhall, MD	25	2027-01-01	2026-10-28
Remimazolam vs Propofol for Motor and Somatosensory Evoked Potentials in Spinal Tumor Surgery Remimazolam, Propofol - Spinal Cord Neoplasms, Spinal Neoplasms	Phase 4	Not yet recruiting	Beijing Tsinghua Chang Gung Hospital	190	2027-01-01	2026-10-28
Immune Modulatory DC Vaccine Against Brain Tumor Immunomodulatory DC vaccine to target DIPG and GBM - Diffuse Intrinsic Pontine Glioma or Glioblastoma	Phase 1	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	10	2026-12-31	2026-08-26
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG) HN2301 injection - Generalized Myasthenia Gravis	Phase 1	Not yet recruiting	Shenzhen MagicRNA Biotechnology Co., Ltd	6	2026-12-31	2026-08-12

Showing 20 of 4080. Sign in to see all of them.

Narrower conditions

Brain Neoplasms (2365)  ·  Glioblastoma (733)  ·  Central Nervous System Neoplasms (696)  ·  Glioma (597)  ·  Astrocytoma (454)  ·  Gliosarcoma (364)  ·  Myasthenia Gravis (319)  ·  Oligodendroglioma (310)  ·  Neoplasms (261)  ·  Meningioma (240)  ·  Breast Neoplasms (224)  ·  Medulloblastoma (208)  ·  Carcinoma, Non-Small-Cell Lung (195)  ·  Pituitary Neoplasms (192)  ·  Sarcoma (177)

Broader conditions

Nervous System Diseases (4060)  ·  Neoplasms by Site (3929)  ·  Neoplasms (3819)  ·  Central Nervous System Diseases (2897)  ·  Brain Diseases (2785)  ·  Central Nervous System Neoplasms (2722)  ·  Neoplasms by Histologic Type (1990)  ·  Neoplasms, Nerve Tissue (1812)  ·  Neuroectodermal Tumors (1540)  ·  Neoplasms, Germ Cell and Embryonal (1534)  ·  Neoplasms, Glandular and Epithelial (1401)  ·  Neoplasms, Neuroepithelial (1297)  ·  Glioma (649)  ·  Pathological Conditions, Signs and Symptoms (611)

Interventions

Temozolomide (260)  ·  Radiotherapy (233)  ·  Radiosurgery (151)  ·  Bevacizumab (129)  ·  Magnetic Resonance Spectroscopy (117)  ·  Carboplatin (90)  ·  Cyclophosphamide (75)  ·  Etoposide (67)  ·  Filgrastim (59)  ·  Vincristine (58)  ·  Irinotecan (54)  ·  Cisplatin (53)  ·  Nivolumab (51)  ·  Radiation (47)  ·  Surgical Procedures, Operative (46)

Sponsors

National Cancer Institute (NCI) (235)  ·  M.D. Anderson Cancer Center (115)  ·  Duke University (80)  ·  Memorial Sloan Kettering Cancer Center (77)  ·  Children's Oncology Group (52)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (51)  ·  Mayo Clinic (50)  ·  St. Jude Children's Research Hospital (45)  ·  European Organisation for Research and Treatment of Cancer - EORTC (42)  ·  Massachusetts General Hospital (37)  ·  Case Comprehensive Cancer Center (33)  ·  Jonsson Comprehensive Cancer Center (30)  ·  Novartis Pharmaceuticals (30)  ·  City of Hope Medical Center (29)  ·  University Health Network, Toronto (27)

Countries

United States (2321)  ·  China (400)  ·  Canada (346)  ·  France (339)  ·  Germany (236)  ·  Italy (221)  ·  United Kingdom (205)  ·  Spain (167)  ·  Netherlands (160)  ·  Australia (134)  ·  Belgium (125)  ·  Switzerland (117)  ·  South Korea (100)  ·  Denmark (92)  ·  Poland (91)

Top investigators

Henry S. Friedman, MD (19)  ·  Brigitte C Widemann, M.D. (14)  ·  Stuart A. Grossman, MD (13)  ·  David A. Reardon, MD (11)  ·  John Boockvar, MD (10)  ·  Maryam Fouladi, MD (10)  ·  Amar Gajjar, MD (9)  ·  Jeffrey J. Raizer, MD (9)  ·  Darell D. Bigner, MD, PhD (8)  ·  Katherine E Warren, M.D. (8)  ·  Roger Stupp, MD (8)  ·  David Peereboom, MD (7)

Results publications

PMID 31401903, PMID 34081125, PMID 19801201, PMID 16757720, PMID 23545055, PMID 25349290, PMID 27243238, PMID 27458945, PMID 30118397, PMID 31809241, PMID 35007270, PMID 37059507, PMID 41213248, PMID 42388397, PMID 14722039, PMID 15117425, PMID 15758009, PMID 16200343, PMID 16648043, PMID 17705175, PMID 17917842, PMID 19556464, PMID 19574236, PMID 19645909, PMID 20694800, PMID 21041710, PMID 21211990, PMID 21584645, PMID 21865400, PMID 22027076, PMID 23243055, PMID 23377664, PMID 23956241, PMID 25098701, PMID 25113840, PMID 25209242, PMID 25303679, PMID 25614945, PMID 25789053, PMID 26148750, PMID 26334749, PMID 26827696, PMID 27488294, PMID 27744512, PMID 28039367, PMID 28592387, PMID 28640703, PMID 29077941, PMID 29122701, PMID 29151359

NIH funding

2023 (28), P30CA033572 (18), U01CA062475 (17), U10CA180886 (17), U01CA081457 (16), U10CA098543 (16), 2019 (14), 2025 (14), 2018 (13), 2015 (12), P30CA043703 (12), 2014 (11), P30CA006973 (11), P30CA138292 (11), UM1CA097452 (11)